Literature DB >> 16954667

Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer.

K Junker1, T Fritsch, A Hartmann, W Schulze, J Schubert.   

Abstract

Bladder cancer is the fifth most common cancer in adults. Because of the high recurrence rate (up to 70%) new tumor markers for urine are necessary for monitoring patients. In this study, we investigated the value of M-FISH on cells from urine for the detection of bladder cancer. Urine samples from 141 patients suspicious of bladder cancer were analyzed in this study. Cells were isolated from urine before surgical therapy. For FISH analysis, a commercial kit (UroVysion) containing hybridization probes for chromosomes 3, 7, 9p21 and 17, was used. Twenty-five cells were analyzed in each case by two observers. A FISH result was obtained in 121 cases. Overall, sensitivity was 60% and specificity reached 82.6%. Sensitivity and specificity by cytology were 24.1% and 90.5%, respectively. Analyzing results concerning T-category, sensitivity of FISH and cytology was 36.1% and 15% in pTa, 65.2 and 25.7% in pT1, 100% and 66.7% in pT2-3 tumors, respectively. Concerning tumor grade, similar results were obtained: sensitivity was 37% and 14% in G1, 65.4% and 40% in G2, 91.7% and 50% in G3 tumors, for FISH and cytology, respectively. In conclusion, FISH on cells from urine has been shown in all studies to be highly sensitive and specific for detection of bladder cancer. Sensitivity of FISH is higher than conventional cytology and can be used in routine diagnosis additionally to conventional cytology especially in doubtful or negative cases. FISH can detect recurrence earlier than other methods like cytology, cystoscopy or biopsy histological examination. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 16954667     DOI: 10.1159/000094214

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  7 in total

1.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

2.  Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study.

Authors:  Nancy P Caraway; Abha Khanna; Ricardo L Fernandez; Linda Payne; Roland L Bassett; Hua-Zhong Zhang; Ashish Kamat; Ruth L Katz
Journal:  Cancer Cytopathol       Date:  2010-10-25       Impact factor: 5.284

3.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

Review 4.  Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement.

Authors:  Bénédicte Clin; Jean-Claude Pairon
Journal:  BMC Public Health       Date:  2014-11-06       Impact factor: 3.295

5.  The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice.

Authors:  Kyung Won Kwak; Sun Hee Kim; Hyun Moo Lee
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

6.  UroVysion fluorescence in situ hybridization (UroVysion FISH) assay for detection of bladder cancer in voided urine of Turkish patients: a preliminary study.

Authors:  Yavuz Dodurga; Cığır Biray Avcı; Sunde Yılmaz; Oktay Nazlı; Ozgür Coğulu; Tufan Cankaya; Cumhur Gündüz
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29

7.  Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood.

Authors:  Angela A G van Tilborg; Lucie C Kompier; Irene Lurkin; Ricardo Poort; Samira El Bouazzaoui; Kirstin van der Keur; Tahlita Zuiverloon; Lars Dyrskjot; Torben F Orntoft; Monique J Roobol; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.